Next Article in Journal
Transformative Potential of Artificial Intelligence in Global Health Policy
Previous Article in Journal
The Role of Stakeholder Involvement in the Evolving EU HTA Process: Insights Generated through the European Access Academy’s Multi-Stakeholder Pre-Convention Questionnaire †
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 11
Issue 1
10.1080/20016689.2023.2218633
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Access to Innovative Drugs and the National Reimbursement Drug List in China: Changing Dynamics and Future Trends in Pricing and Reimbursement

by
Bérengère Macabeo
1,2,*,
Liam Wilson
3,
Jianwei Xuan
4,
Ruichen Guo
5,
Petar Atanasov
6,
Linda Zheng
7,
Clement François
1,8 and
Philippe Laramée
1,2
1
Aix-Marseille Université, Marseille, France
2
Pierre Fabre Group, Paris, France
3
Health Economics and Market Access, Amaris Consulting, Shanghai, China
4
Health Economic Research Institute, Sun Yat-Sen University, Guangzhou, China
5
Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, China
6
Health Economics and Market Access, Amaris Consulting, Barcelona, Spain
7
Pierre Fabre Group, Shanghai, China
8
Putnam Associates, Paris, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2023, 11(1), 2218633; https://doi.org/10.1080/20016689.2023.2218633
Submission received: 27 February 2023 / Revised: 22 May 2023 / Accepted: 23 May 2023 / Published: 13 June 2023

Abstract

ABSTRACT Background and objectives: Multiple reforms aimed at improving the Chinese population’s health have been introduced in recent years, including several designed to improve access to innovative drugs. We sought to review current factors affecting access to innovative drugs in China and to anticipate future trends. Methods: Targeted reviews of published literature and statistics on the Chinese healthcare system, medical insurance and reimbursement processes were conducted, as well as interviews with five Chinese experts involved in the reimbursement of innovative drugs. Results: Drug reimbursement in China is becoming increasingly centralized due to the removal of provincial pathways, the establishment of the National Healthcare Security Administration and the implementation of the National Reimbursement Drug List (NRDL), which is now the main route for drug reimbursement in China. There is also an increasing number of other channels via which patients may access innovative treatments, including various types of commercial insurance and special access. Health technology assessment (HTA) and health economic evidence are becoming pivotal elements of the NRDL decision-making process. Alongside the optimization of HTA decision making, innovative risk-sharing agreements are anticipated to be increasingly leveraged in the future to optimize access to highly specialized technologies and encourage innovation while safeguarding limited healthcare funds. Conclusions: Drug public reimbursement in China continues to align more closely with approaches widely used in Europe in terms of HTA, health economics and pricing. Centralization of decision-making processes for public reimbursement of innovative drugs allows consistency in assessment and access, which optimizes the improvement of the Chinese population’s health.
Keywords: National Reimbursement Drug List; innovative drug access; pricing; reimbursement; decision making; health technology assessment; risk-sharing National Reimbursement Drug List; innovative drug access; pricing; reimbursement; decision making; health technology assessment; risk-sharing

Share and Cite

MDPI and ACS Style

Macabeo, B.; Wilson, L.; Xuan, J.; Guo, R.; Atanasov, P.; Zheng, L.; François, C.; Laramée, P. Access to Innovative Drugs and the National Reimbursement Drug List in China: Changing Dynamics and Future Trends in Pricing and Reimbursement. J. Mark. Access Health Policy 2023, 11, 2218633. https://doi.org/10.1080/20016689.2023.2218633

AMA Style

Macabeo B, Wilson L, Xuan J, Guo R, Atanasov P, Zheng L, François C, Laramée P. Access to Innovative Drugs and the National Reimbursement Drug List in China: Changing Dynamics and Future Trends in Pricing and Reimbursement. Journal of Market Access & Health Policy. 2023; 11(1):2218633. https://doi.org/10.1080/20016689.2023.2218633

Chicago/Turabian Style

Macabeo, Bérengère, Liam Wilson, Jianwei Xuan, Ruichen Guo, Petar Atanasov, Linda Zheng, Clement François, and Philippe Laramée. 2023. "Access to Innovative Drugs and the National Reimbursement Drug List in China: Changing Dynamics and Future Trends in Pricing and Reimbursement" Journal of Market Access & Health Policy 11, no. 1: 2218633. https://doi.org/10.1080/20016689.2023.2218633

APA Style

Macabeo, B., Wilson, L., Xuan, J., Guo, R., Atanasov, P., Zheng, L., François, C., & Laramée, P. (2023). Access to Innovative Drugs and the National Reimbursement Drug List in China: Changing Dynamics and Future Trends in Pricing and Reimbursement. Journal of Market Access & Health Policy, 11(1), 2218633. https://doi.org/10.1080/20016689.2023.2218633

Article Metrics

Back to TopTop